Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Pumps Pipeline With $800M Cardiome Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.
Advertisement

Related Content

Business News, In Brief
Business News, In Brief
Cardiome/Astellas' Kynapid Approval Seems Likely For Limited Indication, If Additional Trial Holds Up
Cardiome/Astellas Kynapid Aiming For Limited Use, With New Trial
Smaller Business Development Deals Are Necessary Counterpoint To Mega-Mergers
Deals Of The Week: BMS/Otsuka, Merck/Cardiome, Sanofi/Medley
Committee Recommends Sanofi’s Multaq For Approval
Schering’s Organon Grab Made Merck's Merger Magic Happen
Cardiome/Astellas Schedule Kynapid Meeting With FDA
Cardiome/Astellas Schedule Kynapid Meeting With FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS069398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel